Cargando…

P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells

Detalles Bibliográficos
Autor principal:	Klingemann, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072113/ http://dx.doi.org/10.1186/2051-1426-2-S2-P24

Ejemplares similares

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
por: Klingemann, Hans, et al.
Publicado: (2016)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

P16. Differential susceptibility of human and mouse NK cells to malignant cell-induced abnormalities in autologous combinations: a potential mechanism for the NK cell-based immunotherapy efficacy
por: Sconocchia, G, et al.
Publicado: (2014)

Promoting NK cell trafficking to improve therapeutic effect of NK cell therapy on osteosarcoma
por: Yang, Yuanzheng, et al.
Publicado: (2015)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

P12. Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses
por: Pellegatta, S, et al.
Publicado: (2014)

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
por: Boissel, Laurent, et al.
Publicado: (2013)

P04-36. HIV-1-speficic antibody dependant cellular cytotoxicity (ADCC) médiated by primary NK cells
por: Delaporte, M, et al.
Publicado: (2009)

P10-07. Extremely rapid degranulation of NK cells activated by HIV-specific antibody dependent cellular cytotoxicity
por: Chung, A, et al.
Publicado: (2009)

P24. Aviscumine enhances NK- cytotoxicity against tumor cells
por: Gamerith, G, et al.
Publicado: (2014)

Ex-vivo expanded human NK cells mediate cytotoxicity and cytokine release against allogeneic cancer cell line by direct recognition and antibody directed cellular cytotoxicity: therapeutic potential use of NK cells for blood and solid tumors
por: Liacini, Abdelhamid, et al.
Publicado: (2014)

P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)
por: Specht, HM, et al.
Publicado: (2014)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Impaired NK and NKT cells immunobiology in rheumatoid arthritis
por: Aggarwal, Ashish, et al.
Publicado: (2012)

Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
por: Koehl, U., et al.
Publicado: (2015)

Technical advances in NK cell-based cellular immunotherapy
por: Fang, Fang, et al.
Publicado: (2019)

TLR-independent activation of NK cells during systemic inflammation
por: Rasid, O, et al.
Publicado: (2014)

KIR/HLA genotype combinations are determinants of Natural Killer (NK) cell mediated antibody-dependent cellular cytotoxicity (ADCC) potency
por: Parsons, MS, et al.
Publicado: (2012)

Reovirus activated NK cells show enhanced cetuximab mediated antibody-dependent cellular cytotoxicity against colorectal cancer cells
por: Zhao, Xing, et al.
Publicado: (2015)

P10-11. NK cells do not accumulate at sites of HIV-replication but show increased activation
por: Luteijn, R, et al.
Publicado: (2009)

P10-12. Altered NK cell phenotype and function in Ugandans with chronic HIV-1 infection
por: Eller, MA, et al.
Publicado: (2009)

Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells
por: Panwong, Suthida, et al.
Publicado: (2021)

KIR-HLA footprints and NK cell-mediated recognition of HIV-1
por: Thobakgale, CF, et al.
Publicado: (2012)

Expression and function of FcγRII on NK cells in rhesus macaques
por: He, X, et al.
Publicado: (2012)

Genomic scale analysis of NK cells impact on response to IFN-α
por: Ascierto, Maria L, et al.
Publicado: (2013)

Periodic fevers associated with celiac disease and marked increase of NK cells
por: Sediva, A
Publicado: (2015)

Substance P and NK(1) receptor activation within the ventral medullary respiratory network prolongs expiratory time
por: Boscan, P, et al.
Publicado: (2001)

CAR-NK cells: A promising cellular immunotherapy for cancer
por: Xie, Guozhu, et al.
Publicado: (2020)

In vitro generation of allo-reactive human NK cells from umblillical cord blood CD34+ progenitor cells
por: Ahn, Yong-Oon, et al.
Publicado: (2015)

CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells
por: Morishima, Chihiro, et al.
Publicado: (2014)

Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire
por: Meazza, Raffaella, et al.
Publicado: (2023)

Human mast cells respond to viral infection by recruiting NK cells and T cells
por: Burke, SM, et al.
Publicado: (2010)

Cbl-b silenced human NK cells respond stronger to cytokine stimulation
por: Lametschwandtner, Guenther, et al.
Publicado: (2015)

NK cells protect TCR-transgenic mice from developing fetal leukemia
por: Dubois, Sigrid, et al.
Publicado: (2014)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)

P522: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
por: Huang, Ruihao, et al.
Publicado: (2023)

Severe peripheral blood lymphopenia without NK cell cytotoxicty deficiency is the rule in adult acquired HLH
por: Carvelli, J, et al.
Publicado: (2015)

Efficacy of adoptive transfer of expanded fetal liver-derived precursor syngeneic and allogeneic murine NK cells against solid tumors
por: Liang, Xiaoyan, et al.
Publicado: (2015)

P1426: WU-NK-101, AN ALLOGENEIC MEMORY NK CELL, FOR THE TREATMENT OF RELAPSE OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Muth, J. J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_84c1og311ok7ceedrfa7ojr9i6